Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse MKT  >  Navidea Biopharmaceuticals Inc    NAVB

NAVIDEA BIOPHARMACEUTICALS INC (NAVB)
Mes dernières consult.
Most popular
  Report  
Delayed Quote. Delayed  - 05/23 09:51:56 pm
0.2395 USD   +1.83%
05/15NAVIDEA BIOPHAR : Reports First Quarter 2018 Financial Results
AQ
05/09NAVIDEA : 1Q Earnings Snapshot
AQ
05/08NAVIDEA BIOPHAR : Reports First Quarter 2018 Financial Results
BU
 SummaryQuotesChartsNewsCalendarCompanyFinancials 
Quotes 5-day view   Delayed Quote. Delayed Nyse Mkt
05/17/2018 05/18/2018 05/21/2018 05/22/2018 05/23/2018 Date
0.235(c) 0.24(c) 0.2386(c) 0.2352(c) 0.2395(c) Last
167 979 241 034 165 273 117 490 217 747 Volume
0.00% +2.13% -0.58% -1.42% +1.83% Change
More quotes
Company
Navidea Biopharmaceuticals, Inc. engages in the development and commercialization of precision immunodiagnostic agents and immunotherapeutic.It is developing multiple precision-targeted products based on their manocept platform to help identify the sites and pathways of undetected disease and... 
More about the company
Latest news on NAVIDEA BIOPHARMACEUTICALS
05/15NAVIDEA BIOPHARMACEUTICALS : Reports First Quarter 2018 Financial Results
AQ
05/09NAVIDEA BIOPHARMACEUTICALS : Management's Discussion and Analysis of Financial C..
AQ
05/09NAVIDEA : 1Q Earnings Snapshot
AQ
05/08NAVIDEA BIOPHARMACEUTICALS, INC. : Results of Operations and Financial Condition..
AQ
05/08NAVIDEA BIOPHARMACEUTICALS : Reports First Quarter 2018 Financial Results
BU
05/08NAVIDEA BIOPHARMACEUTICALS : Schedules First Quarter 2018 Earnings Conference Ca..
AQ
05/07NAVIDEA BIOPHARMACEUTICALS INC : Navidea Biopharmaceuticals to Present at 3rd An..
AC
05/02NAVIDEA BIOPHARMACEUTICALS : Schedules First Quarter 2018 Earnings Conference Ca..
BU
04/19NAVIDEA BIOPHARMACEUTICALS : Signs Deal to Sublicense NAV4694 Worldwide Developm..
AQ
04/19NAVIDEA BIOPHARMACEUTICALS : to Present at 2nd Annual NASH Summit
AQ
More news
Sector news : Biotechnology & Medical Research - NEC
05/18GLAXOSMITHKLINE : Regulators flag possible birth defect link to GSK's HIV drug
RE
05/11Trump's Plan to Cut Drug Prices Leaves Industry Relieved
DJ
05/09Drugmaker GSK rings in more change as CFO heads for exit in 2019
RE
05/08UK biotech firm Autolus joins CAR-T rush with Nasdaq IPO filing
RE
05/03Teva raises 2018 outlook, expects migraine drug approval by year-end
RE
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
05/09Navidea Biopharmaceuticals' (NAVB) CEO Michael Goldberg on Q1 2018 Results - .. 
05/08Navidea Biopharm reports Q1 results 
05/02Cirius Therapeutics completes enrollment in mid-stage study of lead candidate.. 
04/20Key events next week - healthcare 
04/16Navidea signs deal to sublicense NAV4694 worldwide development rights 
Chart NAVIDEA BIOPHARMACEUTICALS
Duration : Period :
Navidea Biopharmaceuticals Technical Analysis Chart | NAVB | US63937X1037 | 4-Traders
Income Statement Evolution
Managers
NameTitle
Mike M. Goldberg President, Chief Executive Officer & Director
Jed Andrew Latkin CFO, COO, Secretary & Treasurer
Frederick O. Cope Chief Scientific Officer & Senior Vice President
Mark I. Greene Independent Director
Michael Yehuda Rice Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
NAVIDEA BIOPHARMACEUTICALS INC-33.05%38
CELLTRION, INC.--.--%31 419
IQVIA HOLDINGS INC4.83%21 259
LONZA GROUP1.41%20 379
INCYTE CORPORATION-29.48%14 109
NEKTAR THERAPEUTICS42.83%14 033